Literature DB >> 2886318

Urinary metabolites of busulfan in the rat.

M Hassan, H Ehrsson.   

Abstract

After ip administration of 15 mg/kg [1,4-14C]busulfan to rat, the urinary excretion was 70% of the total radioactivity after 72 hr. Three major metabolites were isolated and quantified by HPLC. Of the total radioactivity in the urine, unchanged busulfan was excreted as a minor amount (6%) and the following metabolites were identified as: 3-hydroxysulfolane (39%), tetrahydrothiophene 1-oxide (20%), and sulfolane (13%) using GC/MS and NMR spectroscopy. The cytotoxicity of busulfan and its major metabolites was examined using a V79 Chinese hamster cell line.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2886318

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  15 in total

1.  The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity.

Authors:  W E Fitzsimmons; R Ghalie; H Kaizer
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Metabolism of the cysteine S-conjugate of busulfan involves a beta-lyase reaction.

Authors:  Arthur J L Cooper; Islam R Younis; Zoya V Niatsetskaya; Boris F Krasnikov; John T Pinto; William P Petros; Patrick S Callery
Journal:  Drug Metab Dispos       Date:  2008-05-12       Impact factor: 3.922

3.  Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression.

Authors:  Christoph A Ritter; Bernhard Sperker; Markus Grube; Dana Dressel; Christiane Kunert-Keil; Heyo K Kroemer
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 4.  The role of busulfan in bone marrow transplantation.

Authors:  M Hassan
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

5.  Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.

Authors:  L B Grochow; R J Jones; R B Brundrett; H G Braine; T L Chen; R Saral; G W Santos; O M Colvin
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Gas-chromatographic analysis of busulfan for therapeutic drug monitoring.

Authors:  L Embree; R B Burns; J R Heggie; G L Phillips; D E Reece; J J Spinelli; D O Hartley; N J Hudon; J H Goldie
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain.

Authors:  M Hassan; H Ehrsson; I Wallin; S Eksborg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

8.  Pharmacokinetic and metabolic studies of high-dose busulphan in adults.

Authors:  M Hassan; G Oberg; H Ehrsson; M Ehrnebo; I Wallin; B Smedmyr; T Tötterman; S Eksborg; B Simonsson
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.

Authors:  M Hassan; G Oberg; M Björkholm; I Wallin; M Lindgren
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog.

Authors:  J I Brodfuehrer; T J Wilke; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.